Navigation Links
Vanda Pharmaceuticals Appoints Chief Financial Officer

ROCKVILLE, Md., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that it has named James Patrick Kelly as Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the Company.

Mr. Kelly has more than 18 years of experience in financial and operating roles within the healthcare and pharmaceutical industry, most recently as Vice President, Controller at MedImmune, LLC.  He will join Vanda on December 13, 2010.

"We welcome Jim to Vanda and look forward to his financial leadership as we advance our late-stage product pipeline," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda.

Mr. Kelly has been a key member of MedImmune's financial leadership team since 2006.  He joined MedImmune as Director of Sales and Marketing Finance and progressed to the role of Vice President, Controller.  Prior to MedImmune and beginning in 2000, Mr. Kelly was at Biogen Idec serving in research & development finance roles of increasing responsibility, most recently as the Director of Planning and Operations.  In that role, he was the finance leader for the global Development Organization and head of business operations for clinical functions.  While at Biogen Idec he also led the financial management of development and commercial collaborations which included 5 partners, 8 programs, 14 indications and over $1.7 billion in revenue.  From 1997-2000, he was a member of the corporate finance team at Aetna Inc. which held a critical role in mergers and acquisitions and treasury management.  During that period he participated in 11 transactions with a combined value of $20 billion.  He began his life sciences career in 1991 with Janssen Pharmaceutica, a division of Johnson & Johnson.

Mr. Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (ABFO).  He received his Master of Business Administration degree from Cornell University and his Bachelor of Sciences degree in Business Administration from the University of Vermont.

About Vanda Pharmaceuticals Inc:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders.  For more on Vanda, please visit

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):